Targeting hedgehog-driven mechanisms of drug-resistant cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cancer therapy resistance is a major clinical challenge due to cellular plasticity.
• Surviving cancer cells often exhibit altered cell signaling and transcriptional pathways, leading to proliferation and metastasis.
• The Hedgehog (Hh) signaling pathway is implicated in various cancer subtypes and can be aberrantly activated by therapy.

Purpose of the Study:

• To review the current understanding of Hedgehog (Hh) signaling's role in cancer drug resistance.
• To explore mechanisms including non-canonical Gli protein activation and gene amplification conferring chemotherapy tolerance.
• To identify knowledge gaps in the transcriptional regulation of Hh signaling in resistance.

Main Methods:

• Literature review of scientific publications on Hedgehog signaling and cancer drug resistance.
• Analysis of studies investigating Gli protein activation and gene amplification.
• Examination of research on hedgehog-targeted therapies and tool compounds.

Main Results:

• Hedgehog (Hh) signaling is a significant contributor to therapeutic resistance in multiple cancers.
• Non-canonical activation of Gli proteins and gene amplification are key mechanisms of drug tolerance.
• Hedgehog-targeted drugs and tool compounds show potential but require further investigation.

Conclusions:

• Hedgehog (Hh) signaling is a critical factor in cancer drug resistance.
• Further research into the transcriptional mechanisms of Hh signaling is needed to overcome resistance.
• Targeting the Hh pathway offers a promising therapeutic strategy for overcoming cancer drug resistance.